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Abstract 
The cost to healthcare services for the treatment of chronic wounds exceeds $3 
billion per year (Menke et al, 2007). Chronic wounds are frequently colonised by 
nosocomial opportunistic pathogens such as Methicillin-resistant Staphylococcus 
aureus (MRSA). Endogenous androgens are known to contribute to delayed healing 
whilst in contrast, estrogen accelerates healing. Healing in the elderly is impaired, 
particularly in elderly males due to the concomitant decline in estrogen levels yet 
largely unchanged levels of circulating androgens. This is predominantly 
characterised by a prolonged inflammatory phase during wound repair. 
In this study a host-pathogen interaction assay was used to investigate the effect of 
the two main endogenous androgens, testosterone (T) and dihydrotestosterone 
(DHT), on the clearance of MRSA by macrophages derived from U937 monocytes. 
Concentrations of T and DHT were chosen to model adult supraphysiological levels 
following exogenous supplementation (1 x 10-6 M), physiological levels (1 x 10-7 M, 
1 x 10-8 M) and androgen deprivation (1 x 10-9 M). The involvement of androgen 
receptor (AR) activation in bacterial clearance was explored using AR pathway 
inhibitors. 
Supraphysiological and physiological levels of androgens typical of that in adulthood 
significantly (P<0.05; n=24) inhibited phagocytosis of MRSA in a concentration-
dependent manner compared to the untreated negative control. Scanning electron 
microscopy (SEM) confirmed androgens inhibit bacterial internalisation by U937 
macrophages. AR antagonism reversed the effects of T and DHT, significantly 
(P<0.05) enhancing phagocytosis to levels observed in the untreated negative 
control.  
These findings suggest androgens inhibit the resolution of typical wound bacteria by 
impairing macrophage-mediated phagocytosis, a phenomenon that can be reversed 
via direct AR antagonism. More importantly, the 5alpha-reductase inhibitor 
finasteride significantly (P<0.05; n=24) increased the clearance of MRSA, suggesting 
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the inhibition of phagocytosis by T is mediated principally through initial conversion 
of T to DHT, followed by AR activation by DHT. Novel wound dressings that provide 
local blockade of the AR or inhibition of 5alpha-reductase may be potential 
therapeutic treatments to promote the bacterial clearance of colonised wounds in 
elderly males. 
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1.0 Introduction 
1.1 Acute Inflammation  
Inflammation involves the activation of pro-inflammatory cytokine cascades to 
promote the migration of immune cells to the site of trauma, with the aim to remove 
pathogens and debris and promote wound healing. The innate immune system is 
activated immediately following wounding, initiating a local inflammatory response 
where local mast cells undergo degranulation (Koh and DiPietro, 2011). This in turn 
promotes pro-inflammatory cytokine release. Furthermore, it is well documented 
that wounds are commonly hypoxic which in turn stimulates the recruitment of 
further leukocytes to the site of injury (Sen, 2009). As neutrophils are the most 
abundant white cell type in circulation, they are the first inflammatory cells to be 
recruited to the wound. Neutrophils initiate a positive feedback loop by their release 
of pro-inflammatory cytokines, promoting monocyte recruitment and 
differentiation into tissue macrophages (Koh and DiPietro, 2011). 
Macrophages have the critical pro-inflammatory function of phagocytosis in order 
to engulf and destroy invading pathogens or debris. Pattern recognition receptors 
(PRR) on the macrophage cell surface recognise and bind to pathogen–associated 
molecular patterns (PAMPs) on the target pathogen membrane (Aderem, 2003). For 
example, scavenger receptors can recognise surface components such as 
lipopolysaccharide (LPS) on the bacterial membrane (Underhill and Ozinsky, 2002). 
Particle internalisation involves transformation of the actin cytoskeleton inside 
macrophages to allow extensions of its plasma membrane called lamellipodia to 
surround and engulf the pathogen. Protein kinase C and phosphoinositide kinase 
expressed by macrophages aids lamellipodial formations at the site of attachment 
(Aderem, 2003). This in turn activates transcription of genes involved in 
antimicrobial mechanisms such as toxic peptide production that assists in the killing 
and digestion of internalised pathogens (Aderem, 2003). The inflammatory response 
is self-limiting and once the infection has cleared, inflammation resolves as acute 
wound healing progresses (Aderem, 2003). 
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Unlike acute inflammation, chronic inflammation is not beneficial to the host and 
ultimately leads to tissue degeneration. Chronic inflammation is characterise as 
persistent low grade inflammation and can be a result of the following two factors: 
(i) persistent infection leading to unregulated activation of pro-inflammatory 
cytokines and signalling pathways such as Nuclear factor kappa B (NFκB) and (ii) 
dysregulation of anti-inflammatory cytokines aimed to resolve inflammation such as 
Interleukin-17 (IL-17) (Franceschi and Campisi, 2014). 
1.2 Macrophage Biology   
Macrophages are established during embryogenesis and take on multiple 
phenotypical functions in response to a diverse environment during wound healing. 
They are predominantly responsible for host defence, but also carry out functions 
such as inflammation control, growth factor production, cell proliferation and tissue 
restoration (Snyder et al, 2016). 
Macrophages act independently of the adaptive immune system with remarkable 
plasticity (Kono and Rock, 2008). Their main function is to clear the interstitial 
environment of extraneous cellular material (Mosser and Edwards, 2008) through 
the mechanism of phagocytosis, which was discovered over 100 years ago by Nobel 
Prize winner Élie Metchnikoff (Nathan, 2008). Macrophages detect danger signals 
through their toll-like receptors (TLRs) and interleukin-1 receptor (IL-1R), that signal 
through the adaptor molecule called myeloid differentiation primary-response gene 
88 (Mosser and Edwards, 2008). 
Additional metabolic functions of macrophages include clearance of approximately 
2 × 1011 erythrocytes daily to recycle haemoglobin.  Macrophages also play a role in 
other aspects of immunity such as the adaptive branch, where they act as antigen 
presenting cells (APC) to help resolve inflammation (Duque and Descoteaux, 2014). 
Macrophages are subject to change in their phenotype in response to different 
stimulants. The macrophage type 1 (M1) subtype promotes pro-inflammatory 
cytokine release. In comparison, macrophage type 2 (M2) subtype acts in an anti-
16 
 
inflammatory manner to promote inflammation resolution and tissue repair (Mills, 
2012). 
1.3 Classically Activated Macrophages  
Interferon-gamma (IFN-ɣ) is the most predominant cytokine to activate a classical 
M1 macrophage (Figure 1). This initiates the release of pro-inflammatory cytokines 
from the macrophage resulting in increased superoxide anions, oxygen and nitrogen 
to enhance mycobacterial or tumoricidal capacities during phagocytosis (Dale et al, 
2008). Macrophages can be activated by IFN-ɣ alone as some TLR ligands such as LPS 
can also activate Toll-interleukin receptor (TIR) domain-containing adaptor protein, 
resulting in Interleukin beta (IFNβ) production as an alternative to TNF-α (Yamamoto 
et al, 2003).  Downstream genetic transcription pathways initiated during activation 
include signal transducer and activator of transcription (STAT) molecules following 
IFN-ɣ receptor ligation, nuclear factor-κB (NFκB) and mitogen-activated protein 
kinases (MAPKs), which are triggered in response to TLR or TNF receptor ligation 
(O'Shea and Murray, 2008). In contrast, M2 macrophages are stimulated by 
interlukin-4 (IL-4) to promote wound repair (Sica and Mantovani, 2012). 
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Figure 1: Activation of a Classical macrophage (M1). M0 macrophages are activated 
by stimuli such as IFN-ɣ and intracellular pathogens. Downstream pathways are 
initiated through receptor activation including CD40 and CD86. As a result, 
proinflammatory cytokines are secreted such as IL-6 and TNF-α to promote 
pathogen elimination (Atri et al, 2018). 
 
1.4 Acute Wound Healing  
Following injury, restoration of the skin is crucial for infection prevention during 
cutaneous wound healing. It includes 4 key stages; coagulation, inflammation, 
proliferation and remodelling. The end goal of the wound healing process is the 
formation of the mature scar tissue at the site of injury (Lorenz and Longaker, 2008). 
The first phase is coagulation which begins immediately after trauma. This phase is 
characterised by vascular contraction, platelet aggregation and the formation of a 
thrombus due to activation of the coagulation and complement cascades. This 
reduces immediate blood loss by acting as a haemostatic plug (Lorenz and Longaker, 
2008). The surrounding wound tissue along with the newly formed thrombus release 
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pro-inflammatory cytokines, growth factors and potent chemoattractants such as 
transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), and epidermal growth factor (EGF) that promote the 
progression of acute wound repair (Guo and DiPietro, 2010). 
The inflammatory phase is characterised by inflammatory cell recruitment 
(chemotaxis) to the wound site (Campos et al, 2008). Anaphylatoxins C3a and C5a, 
activated via the complement cascade, attract primary immune cells directly from 
the blood stream (Lorenz and Longaker, 2008). 
The primary role of inflammation during wound healing is the clearance of 
pathogens or cellular debris (Guo and DiPietro, 2010). Neutrophil populations peak 
24-36 hours after injury whereas monocytes peak at around 7 days post-wounding 
(Lorenz and Longaker, 2008). Macrophages carry out phagocytosis and release 
cytokines that promote further recruitment and activation of leukocytes. Upon 
clearance of apoptotic cells, macrophage populations undergo a phenotypic change 
to a reparative state that stimulates initiation of the proliferation phase (Mosser and 
Edwards, 2008). 
The proliferation phase begins around 96 hours post injury and is characterised by 
re-epithelization, angiogenesis and extracellular matrix formation (Guo and DiPietro, 
2010 & Lorenz and Longaker, 2008). This phase involves formation of extracellular 
matrix (ECM) by fibroblasts, angiogenesis by endothelial cells and re-epithelialisation 
by keratinocytes (Guo and DiPietro, 2010; Maquart and Monboisse, 2014; Li et al 
2007). 
Finally, after immune cell populations decline the remodelling phase is characterised 
by collagen remodelling and vascular maturation/ regression of newly formed 
capillaries, allowing vascular density to return to normal within the wound. This 
phase can last over a period of months to years and results in a mature scar (Guo 
and DiPietro, 2010). 
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1.5 Impaired Wound Healing  
Wound healing becomes impaired with increasing age, leading to prolonged healing 
and excessive inflammation (Gilliver et al, 2007). Chronic wounds are characterised 
by failure of the skin to regain its anatomic and functional integrity after one month 
of initial trauma (Clinton and Carter, 2015).  Non-healing wounds include diabetic 
foot ulcers, venous ulcers and arterial ulcers (Harding et al, 2002). Non-healing 
wounds affect about 3 to 6 million people in the United States, with the elderly (+ 
65 years) accounting for 85% of cases (Menke et al, 2007). Furthermore, chronic 
wounds give rise to vast health care expenditures, with total costs estimated at more 
than $3 billion per year (Menke et al, 2007). In the UK, chronic wounds cost the NHS 
around £1 Billion annually, £17 million of which is associated with patients with 
diabetic foot ulceration (Harding et al, 2002). With an aging population and type 2 
diabetes on the rise, the costs to healthcare providers is expected to rise 
substantially. As a consequence, there is an urgency to better understand the 
pathology of chronic wounds and develop novel therapies. 
1.6 Biofilms in Wounds 
A biofilm is a structured ecosystem of bacteria surrounded by an exo-polysaccharide 
layer that aids the survival and adherence of bacteria to the wound bed (Clinton and 
Carter, 2015).  Wounds that have biofilms are the most complicated to treat due to 
their polymicrobial nature, meaning traditional antibiotics combinations fail to 
succeed in biofilm clearance (Clinton and Carter, 2015). Biofilms affect 60% of 
chronic wounds compared to 10% of acute wounds, making wound infection one of 
the largest factors that prolong the healing of chronic wounds (James et al, 2008).  
There is increased transfer of antimicrobial genes within biofilms compared to 
normal bacterial colonisation; such genes can be transferred through those of the 
same and different species. This dramatically increases the virulence of the biofilm 
(James et al, 2008). Furthermore, the unique metabolism within the biofilm also 
allows for antimicrobial tolerance, meaning the biofilm can regenerate itself post 
antibiotic therapy at a stronger tolerability level (Fauvart et al, 2011). Once a biofilm 
is established, it is hard to eliminate and leads to a higher rate of persistent and 
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reoccurring chronic wounds. Pathogens and debris from a biofilm can elevate pro-
inflammatory cytokine levels such as interleukin-1 (IL-1) and TNF-α, resulting in a 
prolonged inflammatory phase and tissue destruction (Guo and DiPietro, 2010). 
1.7 MRSA and Wound Infection 
Methicillin resistant Staphylococcus aureus (MRSA) is an opportunistic pathogen 
that asymptomatically colonises humans (Sisirak et al, 2010). MRSA is the most 
common cause for nosocomial infection worldwide (National Nosocomial Infections 
Surveillance System 2004). Fast spread of infection is associated with overcrowding 
in wards, a low nurse: patient ratio and high average patient stays. Post-surgical site 
infections account for 16% of nosocomial infections and up to 40% in developing 
countries, making them the third most common cause of nosocomial infection 
spread (Sisirak et al, 2010). MRSA is one of many bacterial species associated with 
biofilm formation, specifically in wound infections and implanted-devices (Côrtes et 
al 2015). 
1.8 Global Burden of Antimicrobial Resistance 
The 1940s saw the introduction of the ’wonder drug’ penicillin in conjunction with 
chemotherapy to reduce the burden of Staphylococcus aureus (S.aureus) infections. 
It was not long until resistant strains were isolated in the 1950s, caused by the 
enzyme penicillinase that degrades the antibiotic prior to its delivery to target tissue 
(Sisirak et al, 2010). Methicillin was a second line antibiotic to be introduced but 
resistance soon developed due to bacterial acquisition of the penicillin binding 
protein 2a (PBP2a). MRSA soon became resistant to all other antibiotics including 
vancomycin, with vancomycin resistant isolates found in the USA in 2002. Today, 
such resistance patterns make MRSA one of the hardest pathogens to treat, with 
high rates of morbidity and mortality in patients (Sisirak et al, 2010). This of course 
increases the pressure to find alternatives to antibiotics or to expand our knowledge 
of wound healing and infection to identify strategies to reduce the prevalence of 
MRSA infections and the spread of antimicrobial resistance. 
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1.9 Age-Related Impaired Wound Healing  
There is increasing evidence suggesting aging has a negative impact on wound 
healing processes. Studies have found aging to have damaging implications on the 
inflammatory phase of wound healing, such as prolonged inflammation and 
increased protease activity (Gilliver et al, 2007). Other studies observed delayed re-
epithelization and angiogenesis in aged mice compared to young, demonstrating 
negative effects on the latter stages of wound healing such as the proliferative phase 
(Swift et al, 2001). Thus, aging poses threats to the host in terms of increased risk of 
wound infection. 
Further studies have measured the phagocytic abilities of macrophages in a model 
of wound healing using latex beads and sheep erythrocytes (Swift et al, 2001). They 
found 27% fewer macrophages from aged mice were able to carry out efficient 
phagocytosis and those that were phagocytic consumed 37% fewer latex beads 
compared to the young mice control. When replicated using erythrocytes, 22% 
fewer macrophages from aged mice were phagocytic. A 43% decrease in the number 
of erythrocytes ingested per macrophage was observed. Furthermore, this study 
found there was no significant difference in the volume of receptors on the 
macrophage surface, suggesting the decline in phagocytic ability is not due to a 
decline in receptor sites, but a decline in macrophage capabilities through other 
mechanisms (Swift et al, 2001). This study confirmed functional changes in 
phagocytic cells such as macrophages during aging, thereby prolonging wound 
healing and increasing host susceptibility to wound infection. With an aging 
population, these findings highlight the need to expand our knowledge of 
mechanisms driving age-related impaired healing. 
1.10 Sex Differences in Wound Healing  
It has been documented that elderly females heal more quickly compared to elderly 
males, which sparks speculation that sex hormones such as androgens may have 
negative influence on wound healing processes (Ashcroft et al, 1999). Speculation 
first came about when healing of thick incisional wounds was accelerated in 
castrated mice compared to non-castrated, aged matched controls suggesting male 
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hormones such as testosterone increase inflammatory profiles and delay healing 
independent to aging (Ashcroft and Mills, 2002). 
Ashcroft & Mills found a positive correlation between testosterone (T) and wound 
size in elderly humans (Ashcroft and Mills, 2002). This was in agreement with murine 
studies that showed a significant delay in murine wound repair, characterised by an 
enhanced inflammatory response and reduced matrix deposition associated with 
higher levels of Testosterone (T). In contrast, castrated murine subjects had a lower 
inflammatory profile and increased collagen disposition with evidence of 
accelerated wound repair (Ashcroft and Mills, 2002). Collectively, the findings 
demonstrated androgens are negative regulators of the healing process by 
increasing the inflammatory response. 
In females, estrgoen acts as an anti-inflammtory agent that dampens ones 
inflammatory profile thereby accelerating the wound repair process (Ashcroft and 
Mills, 2002). During aging in both males and females humans, estrogen levels decline 
significantly but testosterone levels are relatively sustained in males. The combined 
effect of reduced estogen but sustained testsoterone is associated with a 
pronounced inflammtory profile in elderly human males (Ashcroft and Mills, 2002). 
This is in concordance with increased prevalance of chronic wounds in elderly males 
(Wicke et al 2009). 
1.11 Biosynthesis of Testosterone and Dihydrotestosterone 
Testosterone has 3 modes of action in peripheral tissues (Figure 2): conversion into 
Dihydrotestosterone (5–10%), direct action of T through the androgen receptor (AR) 
in target tissues or aromatization to estrogen (0.2%) with subsequent activity 
through the estrogen receptor (ER). 
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Figure 1: Three modes of action of Testosterone; conversion to Dihydrotestosterone, 
direct action on target tissues via androgen receptor (AR) and conversion to estrogen 
(Wenqing et al, 2007). 
 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) 
are endogenous steroid hormones released into the blood stream from the adrenal 
cortex in response to adrenocorticotropin secretion from the anterior pituitary gland 
(Gilliver et al 2003). It is important to note, DHEAS levels in adult males are 100-500 
times higher than that of testosterone, proving vast opportunity for conversation 
into sex steroid hormones (Figure 3) such as active androgens (Labrie et al, 2000). 
DHEAS is converted to DHEA via the steroid sulphatase enzyme secreted from 
various cell types including macrophages (Gilliver and Wu and Ashcroft, 2003). 
The enzyme 3beta-hydroxysteroid dehydrogenase (3β-HSD) converts DHEA to 
androstenedione (4-DIONE), which is secreted by the adrenal glands in vast 
quantities. The enzyme 17beta-hydroxysteroid dehydrogenase (17β-HSD) is 
responsible for converting 4-DIONE to testosterone. The enzyme 5-alpha reductase 
(5α-R) can additionally convert testosterone to its potent metabolite 
dihydrotestosterone (DHT). Additionally, a second route involves 17β-HSD in 
converting DHEA to androstenediol (5-DIOL) and the enzyme 3β-HSD finalising the 
conversion to testosterone (Gilliver et al, 2003). 
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Figure 2: Pathways involved in the biosynthesis of active androgens from 
dehydroepiandrosterone-sulphate (DHEA-S) (Gilliver et al, 2003). 
 
High activity of enzymes in peripheral tissues such as skin allows T and DHT to be 
localised (Figure 4), resulting in subsequent exposure of androgens to inflammatory 
cells such as macrophages during wound healing (Gilliver et al, 2003). 
 
Figure 3: Location of steroid enzymes in the skin. Underlined enzymes represent high 
enzyme activity (Gilliver et al, 2003). 
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1.12 Androgen Receptor  
The 90kb AR is a member of the nuclear receptor family that functions as an 
intracellular mediator of gene transcription. The structural arrangement of the AR 
(Figure 5) contains 3 domains; the N-terminal domain (NTD), DNA-binding domain 
(DBD), and ligand binding domain (LBD). Active androgens such as T and DHT are the 
most predominant natural steroidal agonists of the AR. These substrates bind to the 
LBD region that undergoes conformational changes to activate intracellular 
signalling, resulting in a biological response. The AR is present in many tissues 
including the skin and immune cells such as macrophages (Ashcroft and Mills, 2002). 
Such observations suggest androgen signalling in local tissues may be implicated in 
the pathophysiology of some androgen-dependent skin disorders (Chen et al, 1998). 
 
 
Figure 4: Structural arrangement of the human androgen receptor. NTD: N-terminal 
domain, DBD: DNA-binding domain, LBD: Ligand binding domain (Wenqing, Juhyun 
and James, 2007). 
 
1.13 Androgen Signalling 
Androgen receptors are located in the cell cytoplasm, complexed to heat shock 
proteins (HSP) (hsp 90, hsp 70, and hsp 56) during their inactive state (Gilliver, Wu 
and Ashcroft, 2003). DHT has higher affinity for the AR and maintains a more stable 
DHT-AR complex compared to that of T, making DHT more potent (Chen et al, 1998). 
Following binding of T/DHT to the AR, a phosphorylation reaction occurs resulting in 
dissociation of HSP and activation of the receptor (Gilliver et al, 2003). There are 2 
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alternate pathways that can occur post-AR activation: genomic signalling and non-
genomic signalling (Gilliver et al, 2003). 
 Genomic signalling: 
Following heat shock protein dissociation, the ligand bound receptor dimerizes, and 
binds to a specific deoxyribonucleic acid (DNA) sequence along the androgen 
response element (ARE). Alternatively the dimer can interact with cofactors which 
assist with transcription regulation (Wilkenfeld et al, 2018). 
 Non- genomic signalling: 
Androgens can act as G-coupled-protein receptors on the membrane surface. Upon 
activation, a series of kinase cascades such as phosphoinositide-3 kinase (PI3K),  
Protein kinase B (AKT), and MAPK can activate the transcription of various genes in 
the nucleus (Wilkenfeld et al, 2018). Collectively, transcription and translation of AR 
dependant proteins can give rise to many cell physiological changes such as 
intracellular calcium influx, upregulation of growth factor receptors and actin 
skeleton changes (Wilkenfeld et al, 2018). 
1.14 Pathophysiology of T and DHT 
Testosterone is the principle male steroid hormone, predominantly made via Leydig 
cells in the testis. Testosterone is vital for male development of bone mass, muscle 
mass and spermatogenesis (Wenqing et al, 2007). Males have approximately ten 
times higher serum testosterone levels compared to females (Gilliver et al, 2003). 
Unlike estrogen, the hormone remains significantly bioactive throughout life 
however declines gradually with age (Ashcroft and Mills, 2002). 
DHT is mainly synthesized in peripheral organs such as the skin, where type one and 
two 5α-reductase is abundant, lying resident in the cytoplasm of a variety cell types 
such as sebaceous glands, epidermis cells, sweat glands and hair follicles (Ashcroft 
and Mills, 2002). 
Testosterone levels are reported to decline slightly after the age of 40 at a rate of 
approximately 0.4%/year in human males (Chen et al, 1998). This may be explained 
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by a decline in testicular function. However DHT, which has a 10-fold higher affinity 
for the AR and exists in the circulation at around 10% of testosterone levels, has 
been found to increase up to 3.5%/year relative to testosterone, although total 
androgen levels decline overall (Chen et al, 1998). This phenomenon may be 
explained in terms of increased 5α-reductase activity, and decreased catabolism of 
DHT (Feldman et al, 2002). 
1.15 Effects of Androgens on Inflammatory Response 
Studies have shown castration of male mice results in a dampened inflammatory 
response characterised by a reduction in TNF-α expression compared to intact 
control subjects (Gilliver et al, 2006).  Castration but not 5α-reductase inhibition 
reduced TNF-α positive cell numbers at day 2 following murine post-wounding 
(Gilliver et al, 2006). This evidence suggests testosterone can enhance levels of TNF-
α, an important pro-inflammatory mediator, independent of DHT (Ashcroft and 
Mills, 2002). 
IL-6 is a key regulator of the inflammatory phase during wound healing. A significant 
decline in mRNA IL-6 expression was detected at day 2 post-wounding in murine 
model wound repair (Gilliver et al, 2006).  Further investigations has shown 
testosterone reverses the effects of castration, significantly increasing IL-6 levels 
(Gilliver et al, 2006). These data supports evidence that testosterone alters wound 
cytokine levels and delays wound healing (Gilliver et al, 2006). 
Previous studies have shown gender gives rise to differences in the immune system. 
Increased production of several pro-inflammatory cytokines, including Interleukin-
12 (IL‐12) and IL‐1β, by LPS‐stimulated monocytes was observed in ex-vivo 
monocytes from males compared to females following incubation with physiological 
concentrations of testosterone (Krummen et al, 2010). These data suggest that male 
gender, in addition to testosterone levels, may prolong the inflammatory phase of 
wound repair (Posma et al, 2004). Testosterone also decreases Toll like receptor 4 
(TLR-4) expression in primary macrophages and macrophage cell lines, thereby 
impairing macrophage function in pathogen recognition (Rettew et al, 2008). 
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In vivo and in vitro experiments conducted in the late 1990s by Mondal and Rai 
showed that DHT suppresses phagocytosis in lizard splenic macrophages in a dose 
and time dependant manner (Mondal and Rai, 1999). 
These data support growing evidence that sex steroid hormones are responsible for 
the differing inflammatory responses between genders. However, such 
phenomenon warrants further exploration using human cells/tissues and 
physiological concentrations of androgens to identify true biological effects and 
underlying mechanisms of action. 
1.16 Androgen Inhibitors 
Anti-androgens such as AR antagonists and 5α-reductase inhibitors are used to treat 
a variety of androgen dependent conditions from acne to prostate cancer (Wenqing 
et al, 2007). Two common AR antagonists are cyproterone acetate (CYP) and 
flutamide (FLU).  The 5α-reductase inhibitor finasteride (FIN) is also used to block 
the conversion of T to DHT (Zhao et al, 2017).  These various inhibitors are often 
used within experiments to investigate androgen-mediated responses in vitro. 
In vitro experiments using CYP in a yeast model have reversed the effects of DHT 
treatment, increasing phagocytic activity of macrophages (Mondal and Rai, 1999). 
These data suggest DHT acts through the AR to bring about negative effects on 
macrophage phagocytosis. However, this response has not been explored in human 
macrophages with physiological concentrations of DHT to date. 
Studies have shown that androgen treatment on guineapig splenic macrophages 
decreases the expression of Fc-gamma receptors (FcɣR) 1&2, thereby decreasing 
their ability to recognise Immunoglobulin type G (IgG) sensitised complexes (Gomez 
et al, 2000). The authors showed that CYP reversed the findings, confirming the 
effect was mediated through the AR. However, CYP has not been explored in the 
context of human wound healing and the clearance of bacteria pathogens such as 
MRSA. 
Flutamide is an acetanilide-derived agent first approved by the FDA in 1989 for 
locally confined metastatic prostate cancer (Haendler and Cleve, 2012). Flutamide is 
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a competitive antagonist of the AR which upon binding blocks androgen activity 
(Sarrabay et al, 2015). Flutamide is one of the desired anti-androgens for 
pharmacological use due to its high specificity for the AR and reduced cross reactivity 
with other ligands. Flutamide is commonly prescribed for prostate cancer since it is 
metabolised to 2-hydroxyflutamide in vivo, which has higher affinity and potency 
compared to flutamide itself (Wenqing et al, 2007). 
In vivo wound healing experiments have shown that flutamide accelerates healing 
by direct dampening of the inflammatory response, characterised by reduced 
macrophage TNF-α messenger ribonucleic acid (mRNA) expression and NF-κB 
activation (Ashcroft and Mills, 2002). 
Although flutamide mimics the effects of castration on wound healing, reducing 
inflammatory and accelerating wound healing, its effect on infection clearance in 
wounds has not been investigated (Ashcroft and Mills, 2002). 
Finasteride blocks the enzyme 5α-reductase that converts T to DHT (Zhao et al, 
2017), with murine wound healing studies showing it can reduce in vivo DHT levels 
threefold (Gilliver et al, 2006). 
In vivo investigations of post-operative prostate wound healing has shown 
finasteride accelerates healing and directly dampens the inflammatory response, 
characterised by reduced TNF-α expression by M1 macrophages, especially within 
the first week (Zhao et al, 2017). Urine analysis showed IL-6, IL-12 and TNF-α were 
reduced during finasteride treatment compared to controls. Similarly, decreased 
TNF-α secretion was observed in AR knockout mice, suggesting the AR is responsible 
for DHT-induced TNF-α secretion by M1 macrophages. Flow cytometry revealed 
finasteride reduces the number of M1 macrophages in the wound area compared to 
controls. To conclude, these data suggest DHT acts through the AR in macrophages 
to mediate an increased inflammatory profile characterised by pronounced TNF-α, 
a phenomenon that can be reversed through exposure to finasteride. 
A murine study by Gilliver et al (2006) shown 5α-reductase inhibition via MK-434 
treatment resulted in a significantly decreased wound area and a considerable 
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decrease in inflammatory cells per unit area, mimicking the effects of castration. 
These findings confirm that DHT impairs murine wound healing, a phenomenon that 
can be reversed through castration or blockage of DHT formation. 
1.17 Anti-Androgens as Therapeutic Strategies for Bacterial Clearance 
To date anti-androgens have not been exploited as potential therapeutic strategies 
to enhance host immune responses and promote the clearance of bacteria. A deeper 
understanding of the mechanisms underlying androgen-mediated inhibition of 
phagocytosis could potentially lead to new therapeutic strategies for bacterial 
infections that promote host responses of the innate immune system, thereby 
reducing the over-reliance on traditional, first-line treatments such as antibiotics. 
Therapeutic success with anti-androgen therapy in the context of wound infections 
could ultimately decrease global mortality rates and annual healthcare expenditure 
on chronic wounds. Such treatments could help fight the emergence of antimicrobial 
resistance by reducing the need for widespread antibiotic usage and minimising the 
prevalence of problematic hospital- and community-acquired infections such as 
MRSA. 
2.0 Aim and objectives 
The aim of this study was to investigate and manipulate the effects of androgens on 
the clearance of MRSA by human macrophages. 
The fundamental objectives of the research were: 
 To generate human-derived macrophages from U937 monocytes. 
 To model both androgen deprivation and supraphysiological/physiological 
ranges of T and DHT in an in vitro phagocytosis assay using U937 
macrophages. 
 To measure the rate of clearance of MRSA by U937 macrophages exposed to 
differing concentrations of androgens. 
 To explore the pathways/mechanisms by which androgens/anti-androgens 
mediate MRSA clearance by U937 macrophages using androgen receptor 
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antagonists and 5α-reductase  inhibition. To visualise androgen-mediated 
effects on phagocytosis by scanning electron microscopy (SEM). 
3.0 Ethical Declarations 
No ethical implications were identified during this research. No aspect of the work 
involved the use of participants, animals or primary human tissues. The study used 
a commercially available U937 monocyte cell line throughout. 
4.0 Materials List 
Bovine Serum Albumin (Sigma-Aldrich, Dorset) 
Cyproterone acetate (Sigma-Aldrich, Dorset) 
Dihydrotestosterone (Sigma-Aldrich, Dorset) 
DMSO (Sigma-Aldrich, Dorset) 
Finasteride (Sigma-Aldrich, Dorset) 
FITC-conjugated anti-human CD11c antibody (Clone Bu15, Biolegend UK) 
Flutamide (Sigma-Aldrich, Dorset) 
Foetal Bovine Serum (FBS) (Sigma-Aldrich, Dorset) 
Glutaraldehyde (Sigma-Aldrich, Dorset) 
Gold (Polaron, SC7640) 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
Interferon-gamma (IFN-γ) (Sigma-Aldrich, Dorset) 
Lipopolysaccharide (LPS) from Escherichia coli (Sigma-Aldrich, Dorset) 
Methicillin-Resistant Staphylococcus aureus - Strain 11 (Hospital isolates, 
Manchester, UK) 
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Nutrient Agar (Oxoid, Basingstoke) 
Nutrient Broth (Oxoid, Basingstoke) 
Paraformaldehyde (Sigma, Dorset) 
Penicillin – streptomycin (Sigma-Aldrich, Dorset) 
Phorbol 12-myristate 13-acetate (PMA) (Applichem, Darmstadt) 
Phosphate Buffered Saline (PBS) (Fisher Scientific, Loughborough) 
RPMI-1640 Media (Lonza, Slough) supplemented with 10% Foetal Bovine Serum 
(Sigma-Aldrich, Dorset) and 2% Penicillin-Streptomycin (Lonza, Slough) 
Saline (Sigma-Aldrich, Dorset) 
Silicon wafers (Sigma-Aldrich, Dorset) 
Testosterone (T) (Sigma-Aldrich, Dorset) 
Trypsin EDTA (Lonza, Slough) 
0.4% Trypan Blue (Lonza, Slough) 
5.0 Methods 
5.1 Bacterial Culture 
Methicillin Resistant Staphylococcus aureus strain 11 (MRSA11) were used in this 
project. One colony of MRSA (Hospital isolates, Manchester, UK) was re-suspended 
into nutrient broth medium (Oxoid, Basingstoke) and cultured for 24 hours in an 
orbital shaker at 37˚C. Broths were centrifuged twice for 10 minutes at 3500 RPM 
and the pellet was washed using saline (Sigma-Aldrich, Dorset). One in ten serial 
dilutions of the NEAT broth were prepared using 9mL of saline. Serial dilutions 10-5, 
10-6 and 10-7 were cultured overnight on nutrient agar plates (Oxoid, Basingstoke) at 
37˚C prior to performing colony counts to determine the bacterial density (colony 
forming units/mL (CFU/mL) of each broth. Each broth was diluted in saline to a 
concentration of 2 x 104 CFU/mL. 
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5.2 Cell Culture 
Immortal U937 human monocytes (0.5 x 106 cells/mL) (Health Protection Agency 
Culture Collections, Salisbury) were cultured (37°C with 5% CO2) under aseptic 
conditions using RPMI 1640 media (Lonza, Slough) supplemented with 10% Foetal 
Bovine Serum (FBS) (Sigma-Aldrich, Dorset) and 2% Penicillin-streptomycin (Sigma-
Aldrich, Dorset). Cells were re-suspended at 0.5 x 106 cells/mL in fresh media every 
48 hours. 
Cell counting was performed during sub-culturing using a Biorad TC10 automated 
cell counter and trypan blue (Lonza, Slough) exclusion method (equal volume of 0.4% 
sterile filtered trypan blue and cell suspension) whereby dead cells absorb the blue 
dye and are excluded from the cell count. Cell viability was maintained above 90% 
for all experiments in line with previous studies (Krzykowska-Petitjean et al, 2012). 
5.3 U937 Monocyte Differentiation Assay 
U937 monocytes at a concentration of 1 x 106 cells/mL were treated with 50 ng/mL 
Phorbol 12-myristate 13-acetate (PMA) (Applichem, Darmstadt) for 72 hours at 37˚C 
and 5% CO2. This induced the differentiation of U937 monocytes to macrophage-like 
cells as described previously (Sproston et al, 2018). 
5.4 Flow Cytometry 
Following treatment with PMA for 72 hours (section 5.3), the U937 cells were 
centrifuged at 500 g for 5 minutes before being washed twice with phosphate 
buffered saline (PBS) (Fisher Scientific, Loughborough). Cells were fixed with 4% 
paraformaldehyde (Sigma, Dorset) in PBS for 15 minutes at room temperature. The 
supernatants were discarded and the cells were washed twice with PBS. Cells were 
then stained with FITC-conjugated anti-human CD11c antibody (Clone Bu15, 
Biolegend UK), (diluted 1:50 with 10% FBS in PBS) at room temperature for 30 
minutes. Cells were washed twice with PBS before resuspension in 500 µL of PBS. 
CD11c expression was measured with a BD Accuri C6F1 cytometer using BD Accuri 
C6 software. Data from three experimental replicates were presented as the median 
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fluorescence intensity (MFI) relative to unstained monocytes (negative control) as 
described previously (Sproston et al, 2018). 
5.5 Host-Pathogen (Phagocytosis) Assay 
Testosterone (T) / Dihydrotestosterone (DHT) Treatments: 
U937 differentiated macrophages were treated (n=24 per treatment) for 24 hours 
at 37°C in 5% CO2 with differing concentrations of T/DHT (Sigma-Aldrich, Dorset) in 
antibiotic free RPMI media to represent supraphysiological concentrations (1 x 10-6 
M), physiological concentrations (1 x 10-7 M and 1 x 10-8 M) and androgen 
deprivation (1 x 10-9 M) or an absolute absence of androgens (negative control) as 
described previously (Gilliver et al, 2006).  
Androgen Pathway Inhibitor Treatments: 
U937 adherent macrophages were treated (n=24 per treatment) with either an AR 
inhibitor (Cyproterone Acetate or Flutamide) or the 5-alpha (5α-) reductase inhibitor 
(Finasteride) (Sigma-Aldrich, Dorset) suspended in RPMI media at concentration 1 x 
10-6 M  for 24 hours at 37°C in 5% CO2. Supernatants were removed and U937 
macrophages were then treated with T/DHT (1 x 10-6 M) for 24 hours before 
performing the host-pathogen assay. 
Host-pathogen Interaction: 
Following treatments with androgens or androgen inhibitors, U937 macrophages 
were stimulated with 50 µL Interferon-gamma/Lipopolysaccharide (IFN-ɣ/LPS) (100 
ng/mL and 1 µg/mL respectively) suspended in antibiotic-free RPMI media for 2 
hours at 37˚C in 5% CO2 as an in vitro model of infection/ inflammation. 
Supernatants were discarded and the U937 macrophages were incubated with 
LPS/IFN-ɣ (Sigma-Aldrich, Dorset) and MRSA (104 CFU) in a total volume of 100 µL 
for 3 hours to allow phagocytosis to take place. The supernatants were aspirated 
and collected. Adherent U937 cells were detached using 450 µL EDTA-Trypsin 
(Lonza, Slough) for 5 minutes before adding 450 µL of RPMI media to neutralise the 
trypsin. The content of each well (900 µL) was then added to the collected 
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supernatant.  Bacterial recovery was determined by culturing a 100 µL aliquot of 
each sample onto duplicate nutrient agar plates and incubating for 24 hours at 37°C 
in 5% CO2. The number of MRSA colonies recovered on the agar plates were used to 
calculate the mean bacterial recovery. 
Controls: 
Bacterial controls (n=24) consisting of MRSA (104 CFU) incubated in 100 µL antibiotic 
(Ab)-free RPMI media at 37oC and 5% CO2 were performed within the assay to take 
into account the rate of bacterial growth in the absence of host (U937 macrophages) 
interaction. Bovine serum albumin (BSA) (Sigma-Aldrich, Dorset) controls and 
androgen inhibitor controls were prepared, consisting of 1 x 10-6 M BSA/inhibitor 
suspended in Ab-free RPMI media and incubated for 3 hours at 37°C in 5% CO2. The 
negative control consisted of macrophages incubated in the absence of androgens 
(absolute absence of androgens). The inhibitor controls were used to determine the 
direct effect of androgen inhibitors on phagocytosis in the absence of T/DHT. 
U937 Cell Counts: 
Total cell counts were performed before the host-pathogen interaction between 
U937 macrophages and MRSA. Cell culture media was removed from one replicate 
well of each treatment/control and U937 macrophages were detached using 50 µL 
of Trypsin-EDTA for 5 minutes. The trypsin was neutralised with 50 µL of Ab-free 
media and a automated cell counter Biorad was used to determine the number of 
total and viable U937 cells (average of two readings) using the trypan blue exclusion 
methodology as described in section 5.2. 
5.6 Statistical Analysis 
Statistically significant differences (P<0.05) in mean bacterial recovery (CFU/mL) 
between treatments and control groups were determined using SPSS software 
(Version 24) by performing normality tests and ANOVA followed by Tukey Pairwise 
comparisons. In all cases P<0.05 was considered statistically significant. 
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5.7 Scanning Electron Microscopy (SEM) 
Silicon wafers (Sigma-Aldrich, Dorset) prepared at size 1 cm2 were sterilised using 
70% ethanol for 30 minutes and allowed to dry in a class II cabinet. PMA-treated 
U937 cells (1 x 106/mL) were added to wells containing the silicon wafers and 
incubated for 72 hours at 37˚C and 5% CO2. The U937 macrophages generated were 
treated with T/DHT and stimulated with IFN-ɣ/LPS (100 ng/mL and 1 µg/mL 
respectively) before being incubated with MRSA for 3 hours as described in section 
5.5. Similarly, controls were generated as described in section 5.5 using silicon 
wafers in control wells. The silicon wafers were removed from each well and placed 
in 4% glutaraldehyde (Sigma-Aldrich, Dorset) at 4°C overnight to allow sample 
fixation. Each silicon wafer was washed with increasing concentrations of ethanol 
(20, 40, 60, 80 and 100% ethanol) for 30 minutes each. Samples were dried overnight 
in a vacuum-assisted desiccator at room temperature. Samples were coated with 
gold (Polaron, SC7640) ready for imaging by a Scanning Electron Microscope (SEM; 
Carl Zeiss Ltd Supra 40VP). 
6.0 Results 
6.1 Flow Cytometry 
Flow cytometry was used to confirm differentiation of U937 monocytes into U937 
macrophages through the detection of surface marker CD11c that is specific to 
macrophage populations. Figure 6 shows low detection of CD11c on monocyte and 
unstained macrophage populations (negative controls). However, PMA-
differentiated cells demonstrated significantly (P<0.01) higher levels of CD11c 
compared to controls [P<0.01]. These data confirmed differentiation of U937 
monocytes into CD11c-positive (CD11c+) U937 macrophages (Figure 6 & 7). 
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Figure 5: Detection of the surface marker CD11c using flow cytometry to confirm 
differentiation of U937 monocytes into macrophages. Differentiated cells expressed 
significantly (n=3; P<0.01) higher levels of the CD11c marker compared to monocyte 
and unstained macrophage controls. The relative Median Florescence Intensity 
(MFI) for unstained monocytes: 1.00; CD11c positive (cD11c+) monocytes: 1.26; 
unstained macrophages: 1.17; CD11c-Positive (CD11c+) macrophages: 3.28. Bars 
represent mean MFI ± standard error of the mean in all cases. * indicates significant 
difference between CD11c+ macrophages and controls. 
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Figure 6: Flow cytometry charts confirming monocytes were differentiated into 
macrophage populations. a) Unstained monocytes. b) Unstained macrophages. c) 
CD11c+ monocytes. d) CD11c+ macrophages. 
 
6.2 Effect of Testosterone on Phagocytosis of MRSA 
A one-way ANOVA identified significant (P=0.01) differences in bacterial recovery 
per million viable macrophages (CFU/mL) between androgen-treated (T: 1 x 10-6 M, 
1 x 10-7 M, 1 x 10-8 M, 1 x 10-9 M) and untreated control groups. 
Bacterial recovery significantly (P<0.01) reduced in the presence of untreated 
macrophages (negative control, NC) compared to MRSA recovery in absence of any 
phagocytes (bacteria alone control), suggesting the U937 macrophages were highly 
effective at phagocytosis in the absence of androgens. 
a b 
c d 
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Tukey pairwise comparison tests showed higher concentrations of testosterone (T: 
1 x 10-6 M, 1 x 10-7 M, 1 x 10-8 M) significantly (P<0.01)  increased bacterial recovery 
CFU/mL in a dose dependant manner (Figure 8) compared to the untreated negative 
control, suggesting testosterone concentrations spanning physiological levels found 
in adult males inhibit phagocytosis. Supraphysiological concentrations of 
testosterone (1 x 10-6 M) resulted in the highest MRSA recovery of 9298 CFU/mL, 
whilst physiological concentrations of testosterone typical of adult males (1 x 10-7 M 
and 1 x 10-8 M) also gave elevated MRSA recoveries of 7583 CFU/mL and 6808 
CFU/mL respectively compared to the untreated NC (1864 CFU/mL). In contrast, 
although the mean MRSA recovery with testosterone deprivation (1 x 10-9 M) was 
elevated (5280 CFU/mL) compared to the untreated NC (absolute absence of 
androgens), there was no evidence to suggest this concentration of testosterone 
significantly inhibited phagocytosis (P=0.08). 
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Figure 7: Effect of Testosterone (T) on the phagocytosis of MRSA by U937 
macrophages (n=24). MRSA recovery significantly (P<0.01) increased in a dose-
dependent manner following exposure of macrophages to testosterone (T: 1 x 10-6 
M, 1 x 10-7 M, 1 x 10-8 M). Bacterial control (B alone) 104 CFU/mL, Negative control 
(NC) 1864 CFU/mL, T: 10-6 M 9298 CFU/mL, T: 10-7 M 7583 CFU/mL, T: 10-8 M 6808 
CFU/mL, T: 10-9 M 5280 CFU/mL. Bars represent mean MRSA recovery per million 
macrophage (CFU/mL) ± standard error of the mean (SEM). * indicates significant 
difference (P<0.01) between T treatment and NC. 
 
6.3 Effect of Dihydrotestosterone (DHT) on Phagocytosis of MRSA 
A one-way ANOVA identified significant (P=0.01) differences in bacterial recovery 
per million viable macrophages (CFU/mL) between DHT-treated (DHT: 1 x 10-6 M, 1 
x 10-7 M, 1 x 10-8 M, 1 x 10-9 M) and untreated control groups. 
Again bacterial recovery significantly (P<0.01) reduced in the presence of untreated 
macrophages (negative control, NC) compared to MRSA recovery in absence of any 
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phagocytes (bacteria alone control), suggesting the U937 macrophages were highly 
effective at phagocytosis in the absence of androgens. 
Tukey pairwise comparison tests showed DHT treatments significantly (P<0.03) 
increased bacterial recovery CFU/mL in a dose dependant manner (Figure 9), 
suggesting concentrations of DHT that span physiological concentrations in adult 
males inhibit phagocytosis. Supraphysiological and physiological  concentrations of 
DHT (1 x 10-6 M, 1 x 10-7 M and 1 x 10-8 M) appeared to almost arrest phagocytosis, 
with the bacterial recovery (9508 CFU/mL, 8505 CFU/mL and 7510 CFU/mL) 
approaching that found in the absence of any phagocytes (bacteria alone control). 
In contrast, DHT concentration 1 x 10-9 M increased the mean MRSA recovery (6429 
CFU/mL) compared to the untreated NC, however shown no evidence to suggest this 
concentration of DHT significantly inhibit phagocytosis (P=0.2). 
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Figure 8: Effect of Dihydrotestosterone (DHT) on the phagocytosis of MRSA by U937 
macrophages (n=24). MRSA recovery significantly (P<0.01) increased in a dose-
dependent manner following exposure of macrophages to DHT (DHT: 10-6 M, 10-7 
M). Bacterial control (B alone) = 104 CFU/mL, Negative control (NC) = 1866 CFU/mL, 
DHT: 10-6 M = 9508 CFU/mL, DHT: 10-7 M = 8605 CFU/mL, DHT: 10-8 M = 7510 
CFU/mL, DHT: 10-9 M = 6429 CFU/mL.  Bars represent mean MRSA recovery per 
million macrophage (CFU/mL) ± standard error of the mean (SEM). * indicates 
significant difference (P<0.01) between DHT treatment and NC. 
 
6.4 Comparison of the Effects of Testosterone (T) and Dihydrotestosterone (DHT) 
on Phagocytosis of MRSA 
Both T and DHT followed the same trend, increasing MRSA recovery compared to 
the untreated negative control (NC). However, on average DHT increased bacterial 
recovery by an additional 8% compared to T (Figure 10).  The data suggest both T 
and DHT inhibited phagocytosis in a dose-dependent manner, with 
supraphysiological concentrations (1 x 10-6 M) of T and particularly DHT almost 
arresting phagocytosis.  Collectively, these findings suggest DHT was substantially 
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more potent at inhibiting phagocytosis than T, with even very low concentrations of 
DHT leading to MRSA persistence. 
 
Figure 9: Comparison of the effect of testosterone (T) and dihydrotestosterone 
(DHT) on the phagocytosis of MRSA. Both T and DHT increased the percentage (%) 
bacterial recovery compared to the bacterial (B alone) and untreated negative 
control (NC) groups (n=24) in a dose-dependent manner. Bacterial Control = 100%, 
Negative Control = 19%, T: 10-6 M = 93% v DHT: 10-6 M = 95%, T: 10-7 M = 76% v DHT: 
10-7 M = 86%, T: 10-8 M = 70% v DHT: 10-8 M = 75%, T: 10-9 M = 53% v DHT: 10-9 M = 
64%. Bars represent mean MRSA recovery per million macrophage (CFU/mL) ± 
standard error of the mean (SEM). 
 
 
Percentage MRSA Recovery (%) 
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6.5 Androgen Receptor Inhibition  
The androgen receptor antagonists, Flutamide (FLU) and Cyproterone acetate (CYP), 
and the 5-alpha (5α-) reductase inhibitor, Finasteride (FIN), were explored to 
determine the potential mechanisms through which androgens mediate 
phagocytosis. 
6.6 Reversal of Testosterone (T)-Mediated Inhibition of Phagocytosis 
U937 macrophages were treated with the androgen inhibitors at a concentration of 
10-6 M prior to exposure to T at concentration of 10-6 M (Figure 11). A one-way 
ANOVA indicated significant differences between treatment groups (P<0.01). The 
bacterial recovery per million viable macrophages (CFU/mL) was significantly 
(P<0.01) lower in inhibitor treated groups (FIN/ FLU/ CYP + T: 10-6 M) compared to T 
treatment group (T: 10-6 M), indicating all the inhibitors block the inhibitory effect of 
T on phagocytosis. All inhibitor treatments showed no statistical significant 
difference (P>0.01) compared to the untreated negative control (NC), confirming the 
addition of inhibitors effectively reverse the inhibitory effects of T on phagocytosis. 
Flutamide was the most effective inhibitor, decreasing bacterial recovery to 1436 
CFU/mL, whilst cyproterone acetate decreased MRSA recovery to 3545 CFU/mL. 
These findings indicate that T acts through the AR to inhibit phagocytosis.  The 5α-
reductase  inhibitor, finasteride (FIN), also decreased MRSA recovery to 3297 
CFU/mL, suggesting the inhibition of phagocytosis by T is mediated principally 
through initial conversion of T to DHT, followed by action of DHT on the AR. 
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Figure 10: Reversal of testosterone (T)-mediated inhibition of phagocytosis via 
androgen receptor (AR) antagonism, using 10-6 M flutamide (FLU) or cyproterone 
acetate (CYP), or via inhibition of 5-alpha (5α-) reductase, using 10-6 M finasteride 
(FIN).  Exposure of macrophages to androgen inhibitors significantly (P<0.01; n=24) 
blocked the effects of T on MRSA recovery. Bacterial control (B alone) = 104, CFU/mL, 
negative control (NC) = 1864 CFU/mL, T: 10-6 M + FIN = 3297 CFU/mL, T: 10-6 M + FLU 
= 1436 CFU/mL, T: 10-6 M + CYP = 3545 CFU/mL. Bars represent mean MRSA recovery 
per million macrophage (CFU/mL) ± standard error of the mean (SEM). * indicates 
significant differences (P<0.01) compared to the T: 10-6 M treatment. 
 
6.7 Reversal of Dihydrotestosterone (DHT)-Mediated Inhibition of Phagocytosis 
U937 macrophages were treated with the androgen inhibitors at a concentration of 
10-6 M prior to exposure to DHT at a concentration of 10-6 M (Figure 12). A one-way 
ANOVA indicated significant differences between treatment groups (P=0.01). The 
bacterial recovery per million viable macrophages (CFU/mL) was significantly 
(P=0.03 for FLU; P=0.01 for CYP) lower following treatment with AR antagonists 
(FLU/ CCYP + DHT: 10-6 M) compared to the DHT treatment (DHT: 10-6 M), suggesting 
the inhibitory effect of DHT on phagocytosis is mediated through the AR.  Flutamide 
and cyproterone acetate treatments reduced MRSA recovery to 3645 and 3076 
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CFU/mL respectively, compared to DHT treatment alone (9507 CFU/mL). Treatment 
with AR antagonists (FLU/CA + DHT: 10-6 M) showed no significant differences 
(P>0.05) compared to the untreated negative control (NC), confirming antagonism 
of the AR reverses the inhibitory effect of DHT on phagocytosis. 
No statistical significance (P>0.05) was found between treatment with the 5α-
reductase  inhibitor finasteride (FIN + DHT: 10-6 M) and treatment with DHT alone 
(DHT: 10-6 M), confirming the enzymatic conversion of T to DHT by 5α-reductase  is 
only relevant following treatment with T (Figure 12) but not with DHT treatment. 
 
Figure 11: Reversal of dihydrotestosterone (DHT)-mediated inhibition of 
phagocytosis via androgen receptor (AR) antagonism, using 10-6 M flutamide (FLU) 
or cyproterone acetate (CYP). Exposure of macrophages to androgen receptor 
antagonists significantly (P<0.01; n=24) blocked the effects of DHT on MRSA 
recovery. Treatment with the 5-alpha (5α-) reductase inhibitor, finasteride (FIN), had 
no significant (P>0.05; n=24) effect on DHT-mediated MRSA recovery.  Bacterial 
control (B alone) = 104 CFU/mL, negative control (NC) = 1864 CFU/mL, DHT: 10-6 M = 
9507 CFU/mL, DHT: 10-6 M + FIN = 8540 CFU/mL, DHT: 10-6 M + FLU = 3645 CFU/mL, 
DHT: 10-6 M + CYP = 3079 CFU/mL. Bars represent mean MRSA recovery per million 
macrophage (CFU/mL) ± standard error of the mean (SEM). * indicates significant 
differences (P<0.05) compared to the DHT: 10-6 M treatment. 
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6.8 Experimental Controls  
Several experimental controls (n=24 in each control group) were performed within 
the phagocytosis assays to ensure robustness of the data (Figure 13). The bacterial 
control (B alone) represents normalised MRSA recovery (104 CFU/mL) in absence of 
androgens (T/DHT) and U937 macrophages.  The negative control represents 
bacterial recovery following incubation with untreated U937 phagocytes (i.e. 
macrophages with no androgen treatment).  The bacterial recovery was reduced by 
81% (P<0.01) in the negative control compared to the bacterial control, indicating 
phagocyte function was highly effective in the absence of androgens. The BSA 
control represents macrophages treated with bovine serum albumin (BSA) instead 
of androgens to confirm changes in MRSA recovery were due to the specific activity 
of androgens. The BSA control had no effect on MRSA recovery (P>0.05) compared 
to the negative control, confirming phagocyte function was unaffected by this non-
androgen treatment. Inhibitor controls represent treatment with androgen 
inhibitors (FIN, FLU and CYP) alone (in the absence of androgens). The inhibitor 
controls had no effect on MRSA recovery compared to the negative control, 
demonstrating the inhibitors had no direct effect on phagocytosis themselves, in the 
absence of androgens. 
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Figure 12: Experimental controls for the phagocytosis assay. MRSA recovery per 
million viable macrophage (CFU/mL) was unaffected by the non-specific BSA control 
or inhibitor control treatments compared to the untreated negative control (NC). 
Bacterial control (B alone): = 104 CFU/mL.  Negative control (NC): = 1864 CFU/mL. 
BSA control: = 1886 CFU/mL. Finasteride (FIN) control: = 2734 CFU/mL, Flutamide 
(FLU) control: = 2510 CFU/mL, Cyproterone acetate (CYP) control: = 2632 CFU/mL. 
No significant differences were found between the BSA/inhibitor control treatments 
and the NC. Bars represent mean MRSA recovery per million macrophage (CFU/mL) 
± standard error of the mean (SEM). 
 
6.9 Scanning Electron Microscopy (SEM) 
SEM was used capture visual evidence of phagocytosis taking place after 3 hours of 
host-pathogen interaction. Figures 14, 15 and 16 illustrate macrophage activity 
under the following conditions, i) absence of androgens (untreated negative 
control), ii) presence of T and iii) presence of DHT. 
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Figure 13a & 14b: SEM image to visualise host-pathogen interaction in the absence 
of androgens (untreated negative control).  Frequent internalisation of MRSA was 
acompanied by prominent membrane extensions (example shown in red circle) by 
the U937 macrophages, typical of phagocytosis. 
 
14a 
14b 
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Figure 14a & 15b. SEM image of host-pathogen interaction in the presence of 
testosterone (T). Internalisation of MRSA was reduced compared to the untreated 
negative control, with fewer macrophage-bacteria interactions suggesting impaired 
phagocytosis. Phagocyte morphology was altered compared to the untreated 
negative control, with macrophages producing fewer and shorter membrane 
extensions (example shown inside red circle). 
 
15a 
15b 
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Figure 15a & 16b. SEM image of host-pathogen interaction in the presence of 
dihydrotestosterone (DHT).  Internalisation of MRSA by U937 macrophages was 
substantially diminished compared to the untreated negative control, with fewer 
macrophage-bacteria engagements, suggesting impaired phagocytosis. Phagocyte 
morphology was altered compared to the untreated negative control, with negligible 
membrane extensions from macrophages (example shown inside red circle). 
16a 
16b 
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7.0 Discussion and Future Work 
This study investigated for the first time the effects of the two main active androgens 
(T or DHT) on the clearance of MRSA by human-derived phagocytes. This novel data 
showed physiological and supra-physiological levels of both T and DHT significantly 
(P<0.05; n=24) reduce the clearance of MRSA in a dose dependent manner. Thus, 
the findings suggest androgens modulate pathways that directly or indirectly inhibit 
phagocytosis by activated U937 macrophages in vitro. DHT was 12% more effective 
at exhibiting inhibitory effects on phagocytosis, which is consistent with the known 
biology of DHT being a more potent metabolite of testosterone, formed through the 
conversion to T to DHT by the enzyme 5α-reductase (Chen et al, 1998).  More 
importantly, the 5α-reductase inhibitor finasteride (FIN) significantly (P<0.05;  n=24) 
increased the clearance of MRSA to levels seen in the untreated negative control, 
suggesting the inhibition of phagocytosis by T is mediated principally through initial 
conversion of T to DHT, followed by the action of DHT on the AR. Thus, collectively 
the findings indicate that DHT (rather than T) is the principle androgen mediating 
the impairment of phagocyte function. Given T declines more slowly than estrogen 
during male ageing, resulting in the relative (%) amount of DHT effectively increasing 
(although absolute levels decline) with age, these data support growing evidence 
that an imbalance of sex hormones during male ageing contributes to impaired 
healing processes and increased propensity of elderly males to develop chronic 
wounds (Ashcroft and Mills, 2002; Gilliver et al, 2006; Gilliver et al, 2003). 
SEM imaging provided qualitative data confirming impaired Internalisation of MRSA 
following treatment with T and DHT compared to the untreated negative control, 
with fewer macrophage-bacteria interactions suggesting impaired phagocytosis. 
Phagocyte morphology was altered following T and particularly DHT treatment 
compared to the untreated negative control, with macrophages producing fewer 
membrane extensions towards bacteria. Formation of lamellopodia by phagocytes 
is a key morphological process required for the engagement and subsequent 
engulfment of bacteria (Aderem, 2003; Rossi et al, 1998). T and particularly DHT 
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treatments appear to interfere with this critical process and block the internalisation 
of bacteria, in concordance with a previous study by Mondal and Rai (1999). 
The underlying mechanism by which androgens inhibit the phagocytic function of 
macrophages is poorly defined but previous studies suggest it is mediated via the AR 
(Gilliver et al, 2006; Mondal and Rai 1999). In a murine model of wound healing, the 
competitive AR antagonist FLU was shown to dampen the inflammatory profile and 
accelerate healing by decreasing levels of TNF-α mRNA expression and NF-κB 
activation, reversing the effects observed with T treatment (Ashcroft and Mills, 
2002). However, FIN has anti-androgenic effects by targeting the enzyme 5α-
reductase, thereby inhibiting the conversion of T to DHT. A study by Gilliver et al 
(2006) found treatment with FIN reversed the effects of T, significantly accelerating 
murine wound healing by reducing the inflammatory response. Collectively, these 
findings suggest that the detrimental effects of T on wound healing require the initial 
conversion of T into DHT, followed by activation of the AR by DHT.  
Similarly, CYP is an AR antagonist that has been shown to increase the phagocytosis 
of yeast cells by non-human splenic macrophages in vitro, reversing the effects of 
DHT (Mondal and Rai 1999). This study has shown the AR antagonists (FLU and CYP) 
significantly (P<0.05; n=24) increased the phagocytosis of MRSA in the in vitro model 
of host pathogen interaction following treatment with T or DHT. These data suggest 
active androgens inhibit phagocytosis by macrophages directly or indirectly through 
AR activation, in a similar manner to androgen activity found in murine wound 
healing studies. More importantly, this study investigated whether the conversion 
of T to DHT is required to inhibit phagocytosis. In concordance with wound healing 
investigations (Gilliver et al, 2006), novel findings from this study showed blocking 
the conversion of T to DHT with finasteride reversed the inhibition of phagocytosis 
observed with T. These findings suggest that the inhibition of phagocytosis by T is 
mediated principally through initial conversion of T to DHT, followed by AR activation 
by DHT. Future work could measure DHT levels produced by macrophages following 
incubation with T to confirm this finding. It is important to note, finasteride was 
unable to reverse the inhibition of phagocytosis following treatment with DHT, 
which is logical since 5α-reductase inhibition can block the conversion of T to DHT 
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but has no effect on pre-existing DHT. Inhibition of phagocytosis following DHT 
treatment was only reversed by antagonism of the AR. 
The SEM from this study supports growing evidence that androgens can alter 
macrophage surface morphology. AR activation may result in decreased 
transcription of pathogen recognition receptors (PPRs) such as TLR-4 and CD14 on 
the macrophage surface, thereby decreasing their ability to detect pathogens and 
carry out phagocytosis (Rettew et al, 2008). To investigate this idea further, future 
work could involve flow cytometry to explore differences in surface receptor 
expression following treatment of macrophages with active androgens.  
Other areas of potential interest arising from the SEM data includes androgen-
induced changes in the cytoskeleton of phagocytes. Androgens have been shown to 
alter the distribution of actin in the cytoskeleton (Papakonstanti et al, 2003), which 
might impair the formation of lamellopodia by macrophages during host-pathogen 
interactions. Mediators involved in lamellopodial formation, such as focal adhesion 
kinase (FAK) and Rac1 (Kallergi et al, 2007) could be investigated in future work to 
determine the downstream mechanisms by which androgens may alter host-
pathogen interactions. Stimulation of the AR with physiological concentrations of 
androgens may inhibit phagocytosis through signalling pathways such as the cAMP 
pathway. Elevation of intracellular cAMP may induce phenotypic changes known to 
alter cell shape and the disassembly of structures involved in pathogen engulfment 
such as membrane extensions (Rossi et al, 1998). Future work could involve 
measuring cAMP levels in phagocytes following treatment with androgens. 
This research studied the effects of androgens typical of adulthood on phagocytosis 
using the immortal commercially available U937 monocyte cell line. These assays 
should be confirmed using ex vivo human peripheral macrophages derived from the 
circulation of age-matched, healthy control male subjects. An in vivo murine model 
of wound healing could also be conducted, similar to that of Gilliver et al (2006), to 
investigate the effect of local DHT application on bacterial clearance within acute 
wounds inoculated with MRSA.   
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8.0 Conclusion 
It is well established that estrogen has a pivotal role in the acceleration of wound 
repair whereas androgens exhibit the opposite effect. During male aging, the decline 
in sex hormone precursors but somewhat maintained levels of androgens in 
circulation from gonadal production result in a substantial reduction in estrogen 
compared to T and DHT. This imbalance in sex hormones potentially explains why 
elderly men heal poorly compared to age-matched females and why there is greater 
male susceptibility to chronic wounds. Studies have demonstrated the effects of 
androgens on wound healing, particularly the heightened inflammatory profile. 
However, the effects of androgens on infection clearance have not been fully 
explored to date.  
This study demonstrated for the first time that endogenous androgens inhibit 
phagocytosis in a macrophage-MRSA model of host-pathogen interaction through 
activation of the AR by DHT. SEM imaging confirmed reduced MRSA-macrophage 
interaction following androgen treatment and this was associated with altered 
phagocyte morphology involving fewer and shorter lamellopodia. These findings 
warrant further investigations to determine the precise underlying cellular 
processes and molecular mechanisms involved in androgen-mediated inhibition of 
phagocytosis. 
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9.0 Impact 
The novel data in this study suggests local AR antagonism (e.g. using flutamide) or 
inhibition of 5α-reductase activity could be potential therapeutic strategies to 
promote the resolution of infected wounds in elderly males, including biofilms 
associated with chronic wounds and wounds that become colonised by antibiotic-
resistant pathogens. Effective treatment of such wounds could save healthcare 
services over £4 billion worldwide, alongside reducing pressure on medical 
resources and hospital bed space.  
Blocking the conversion of T to DHT locally at the wound site may bring potential 
benefits in terms of infection clearance without causing systemic side effects such 
as a reduction in bone and muscle-mass typically observed following androgen 
deprivation (Toraldo et al, 2010). It is well known that 5α-reductase is expressed 
locally in peripheral tissues such as skin (Gilliver et al, 2003). Thus, potential 
therapies to promote bacterial clearance could include specialised wound dressings 
or topical creams containing 5α-reductase inhibitors such as finasteride that can 
deliver the required therapy directly to the wound site. 
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